spacer
home > ict > winter 2017 > focal point
PUBLICATIONS
International Clinical Trials

Focal Point

Most efforts to enhance trial processes hope to bridge the gap between the biopharmaceutical sector and individuals living with a disease. To date, clinical operations (ClinOps) have only been a small part of these attempts, but there is huge potential for them to increase the patient centricity of study execution and, in turn, the satisfaction of patients.

There are three primary advantages of taking a patient-centric approach to ClinOps (see full PDF for Figure 1). First, they can reduce leakage through the enrolment process to increase retention and minimise the pressure on recruiting new subjects. Second, ClinOps are uniquely positioned to manage protocol compliance to avoid costly amendments, and ensure that patients remain in the trial as long as they stand to benefit from it. Finally, with access to real time patient-level data, ClinOps are able to quickly respond to any safety and logistical issues by dedicating additional resources to the studies and sites most in need.

The notion that ClinOps can have a major impact on the patient experience is not particularly new – but access to high-quality, real time and cross-study insights is. The arrival of a new class of software – called clinical intelligence – that aggregates disparate trial data to deliver information on key performance indicators for clinical research teams has been heralded as a significant technological achievement.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Bruno Gagnon is co-author and former Vice President of Clinical Operations at BioMarin. As a 25-year industry veteran, Bruno now spends most of his time as an Executive Consultant, leading emerging life sciences companies and teaching at San Francisco State University in the Clinical Trial Design and Management Certificate Program.

Nick Payton is co-author and leads the Marketing department at Comprehend. The company provides cloud clinical intelligence software to enable leading life sciences organisations to deliver trials more quickly and with improved data quality.

spacer
Bruno Gagnon
spacer
spacer
spacer
Nick Payton
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Cidara Therapeutics Doses First Patient in Pivotal Phase 3 ReSPECT Trial of Rezafungin for Prevention of Invasive Fungal Disease in Patients Undergoing Allogeneic Blood and Marrow Transplantation

SAN DIEGO, Calif. & CAMBRIDGE, England, May 20, 2020 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, and Mundipharma today announced that the first patient has been dosed in its ReSPECT pivotal Phase 3 clinical trial evaluating the efficacy and safety of the company’s lead antifungal candidate, rezafungin, for the prevention of invasive fungal disease in patients undergoing allogeneic blood and marrow transplantation (BMT). Rezafungin is a novel, once-weekly echinocandin being developed for both the treatment and prevention of severe fungal infections.
More info >>

White Papers

Soothing the Logistical Headache of Clinical Trials

Equilibrium Travel Management

As many as 30 per cent of subjects on phase three clinical studies drop out.  Gruelling schedules, high travel costs and time waiting for expense reimbursement can all be factors in these fall rates, and this can be very problematic, delaying or even leading to the cancellation of the trial.  It is crucial to keep subjects motivated, and through efficient travel and expense management, this can be achieved.
More info >>

 
Industry Events

Formulation and Drug Delivery Series UK

8-9 July 2020, Oxford Global

This event brings together leading formulation, drug delivery and biologics manufacturing experts from around the world across two days. The panel of prominent industry leaders and world-leading scientists will share the latest case studies, innovative developments for novel therapeutic products and strategies for drug development.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement